BRPI0418294A - composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes - Google Patents

composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes

Info

Publication number
BRPI0418294A
BRPI0418294A BRPI0418294-4A BRPI0418294A BRPI0418294A BR PI0418294 A BRPI0418294 A BR PI0418294A BR PI0418294 A BRPI0418294 A BR PI0418294A BR PI0418294 A BRPI0418294 A BR PI0418294A
Authority
BR
Brazil
Prior art keywords
poloxamers
pharmaceutical compositions
low solubility
solid pharmaceutical
stabilizing polymers
Prior art date
Application number
BRPI0418294-4A
Other languages
English (en)
Inventor
Marshall David Crew
Ravi Mysore Shanker
Daniel Tod Smithey
Warren Kenyon Miller
Dwayne Thomas Friesen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0418294A publication Critical patent/BRPI0418294A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçõES SóLIDAS FARMACêUTICAS ESTABILIZADAS DE MEDICAMENTOS DE BAIXA SOLUBILIDADE, POLOXáMEROS E POLìMERO ESTABILIZANTES Composições sólidas com maior estabilidade física compreende um medicamento amorfo de baixa solubilidade, um poloxâmero e um polímero estabilizante. As composições proporcionam boa estabilidade física durante o armazenamento e aumento de concentração do medicamento dissolvido quando administrado a um ambiente aquoso de uso.
BRPI0418294-4A 2003-12-31 2004-12-20 composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes BRPI0418294A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53384803P 2003-12-31 2003-12-31
PCT/IB2004/004260 WO2005065656A2 (en) 2003-12-31 2004-12-20 Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers

Publications (1)

Publication Number Publication Date
BRPI0418294A true BRPI0418294A (pt) 2007-05-02

Family

ID=34748971

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418294-4A BRPI0418294A (pt) 2003-12-31 2004-12-20 composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes

Country Status (9)

Country Link
US (1) US20070148232A1 (pt)
EP (1) EP1701703B1 (pt)
JP (1) JP2007517015A (pt)
AT (1) ATE500819T1 (pt)
BR (1) BRPI0418294A (pt)
CA (1) CA2551254A1 (pt)
DE (1) DE602004031767D1 (pt)
MX (1) MXPA06007512A (pt)
WO (1) WO2005065656A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142404A1 (en) * 2004-08-31 2009-06-04 Pfizer Inc Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
EP1904067B2 (en) * 2004-12-03 2017-10-11 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
WO2007060540A1 (en) * 2005-11-25 2007-05-31 Aurobindo Pharma Limited Stable dosage forms of an antidepressant
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
KR20080062430A (ko) * 2006-12-29 2008-07-03 에스케이케미칼주식회사 보관안정성이 우수한 아토르바스타틴 함유 경구투여용 제제
DK2200588T3 (da) * 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
JPWO2010107040A1 (ja) * 2009-03-19 2012-09-20 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
JP5654002B2 (ja) 2009-05-13 2015-01-14 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリエーテルに基づくコポリマーを微水溶性ポリマーと組み合わせて含む固体医薬調製物
EP2477606A1 (de) * 2009-09-18 2012-07-25 Basf Se Schnell lösliche feste pharmazeutische zubereitungen enthaltend amphiphile copolymere auf basis von polyethern in kombination mit hydrophilen polymeren
US9649311B2 (en) 2009-10-26 2017-05-16 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
CN102918039B (zh) * 2010-03-11 2017-06-09 惠氏有限责任公司 甲基纳曲酮的口服制剂和亲脂盐
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
CN104721141A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 抗真菌药物固体分散体
CA2954064C (en) 2014-07-02 2018-10-30 The Research Foundation For The State University Of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
US20160200925A1 (en) * 2015-01-08 2016-07-14 Canon Kabushiki Kaisha Image recording method, ink, and liquid composition
GB2584341B (en) * 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
HUP0201450A3 (en) * 1999-12-08 2003-02-28 Pharmacia Corp Chicago Solid-state form of celecoxib having enhanced bioavailability, pharmaceutical compositions containing it and their preparation
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
EP1276465B1 (en) * 2000-04-20 2014-03-12 Jagotec AG Improved water-insoluble drug particle process
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
KR20020014570A (ko) * 2000-08-18 2002-02-25 김충섭 고체분산화시킨 무정형 이프리플라본의 제조방법
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
CN1625397A (zh) * 2002-02-01 2005-06-08 辉瑞产品公司 胆固醇酯转移蛋白抑制剂的控制释放药物剂型
GB2394417A (en) * 2002-10-24 2004-04-28 Novartis Ag Solid dispersion comprising a piperidine substance P antagonist and a carrier

Also Published As

Publication number Publication date
EP1701703B1 (en) 2011-03-09
DE602004031767D1 (de) 2011-04-21
ATE500819T1 (de) 2011-03-15
WO2005065656A2 (en) 2005-07-21
JP2007517015A (ja) 2007-06-28
US20070148232A1 (en) 2007-06-28
WO2005065656A3 (en) 2006-07-13
EP1701703A2 (en) 2006-09-20
MXPA06007512A (es) 2006-08-31
CA2551254A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
BRPI0418294A (pt) composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes
CY1123724T1 (el) Φαρμακευτικη συνθεση για τροποποιημενη αποδεσμευση
EA200301250A1 (ru) Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
ES2422681T3 (es) Formulación de fármaco de moléculas pequeñas de liberación prolongada
CY1118873T1 (el) Φαρμακευτικη δοσολογικη μορφη μιας φαρμακευτικα αποδεκτης ενωσης διαλυτοποιησης
AR044926A1 (es) Sistema de suministro de farmacos gelificante in situ
CY1106637T1 (el) Υψηλης συγκεντρωσης σταθερα διαλυματα μελοξικαμης για ενεση ανευ βελονας
EA200200431A1 (ru) Фармацевтические композиции, обеспечивающие повышенные концентрации лекарства
EA200201254A1 (ru) Высококонцентрированные стабильные растворы мелоксикама
JP2005289996A5 (pt)
WO2005065657A3 (en) Solid compositions of low-solubility drugs and poloxamers
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
ATE427760T1 (de) Erodierbare polymere zur injektion
RU2016139373A (ru) Растворы бупренорфина с замедленным высвобождением
PE20040865A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
ES2531241T3 (es) Composición farmacéutica líquida estable a base de trazodona
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
ES2625873T3 (es) Método de preparación de micropartículas biodegradables que contienen fármacos
ATE526012T1 (de) Pharmazeutische formulierungen von meloxicam
TN2010000008A1 (en) Oral pharmaceutical solutions containing telbivudine
WO2004039411A3 (en) Solid and semi-solid polymeric ionic conjugates
Patel et al. Formulation Evaluation and optimization Of stomach specific in situ gel of Ranitidine hydrochloride

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.